Related Experiment Video
Updated: Jun 30, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)
Michael Wysota1, Marina Konopleva2, Shane Mitchell3
1Department of Oncology, Montefiore Medical Center, 111 East 210 Street, Bronx, NY, 10467, USA. mwysota@montefiore.org.
Purpose Of Review:
This review seeks to identify and describe novel genetic and protein targets and their associated therapeutics currently being used or studied in the treatment of acute myeloid leukemia (AML).
Recent Findings:
Over the course of the last 5-6 years, several targeted therapies have been approved by the FDA, for the treatment of both newly diagnosed as well as relapsed/refractory AML. These novel therapeutics, as well as several others currently under investigation, have demonstrated activity in AML and have improved outcomes for many patients. Patient outcomes in AML have slowly improved over time, though for many patients, particularly elderly patients or those with relapsed/refractory disease, mortality remains very high. With the identification of several molecular/genetic drivers and protein targets and development of therapeutics which leverage those mechanisms to target leukemic cells, outcomes for patients with AML have improved and continue to improve significantly.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Differentiation of Common Myeloid Progenitor Cells
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Abnormal Proliferation
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

